Pay in 4 interest-free payments of $7.00 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
High-dose semaglutide (up to 16 mg) in people with type 2 diabetes and overweight or obesity: a randomized, placebo-controlled, phase 2 trial
Your healthcare provider may suggest checking vitamin D levels and recommending supplementation if appropriate
A oncedaily pill with doubledigit weight loss over 72 weeks fundamentally changes the accessibility equation for millions who were unwilling or unable to start injectable therapy
B12 testing may be complicated by semaglutide interfering with assay results Clinical Implications This study starts to validate what we've observed in practice: GLP-1s create predictable nutritional challenges that demand proactive, not reactive, intervention
Providers at Found are generally board-certified in obesity medicine or have specific training in metabolic health, which means the clinical evaluation tends to be more nuanced than platforms that rely primarily on general practitioners or nurse practitioners
US$ 28.22
US$ 26.95
US$ 22.07
US$ 25.98
US$ 22.70
US$ 25.44
